Foundational Approach to Cardio-Renal-Metabolic Risk Management: 5-years of Learnings From EMPA-REG OUTCOME

Type 2 diabetes (T2DM) patients have a higher prevalence of cardiovascular (CV) and renal morbidity and mortality, emphasizing the need for new strategies for reno-CV protection. In recent years new-age antidiabetic drugs; the sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated cardioprotective and renoprotective effects. 1 The EMPA-REG OUTCOME study has stated promising results for use of the empagliflozin, an SGLT2 inhibitor, showing CV outcome benefits in T2DM patients with and without known CV diseases or heart failure (HF) history.

2 The EMPEROR‐Reduced study is underway to evaluate the effect of empagliflozin on re ducing the rate of worsening of renal function in addition to the effect on the risk of CV morbidity and mortality in patients with established symptoms of HF. 3 The findings from these studies are likely to advance T2DM treatment options, by…